These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 14981022)

  • 1. Two markers complement each other in identifying risk.
    SoRelle R
    Circulation; 2004 Feb; 109(7):e9012. PubMed ID: 14981022
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting cardiovascular risk: so what do we do now?
    Lloyd-Jones DM; Tian L
    Arch Intern Med; 2006 Jul; 166(13):1342-4. PubMed ID: 16831997
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New test predicts heart risk.
    FDA Consum; 2003; 37(5):6. PubMed ID: 14666894
    [No Abstract]   [Full Text] [Related]  

  • 5. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
    Folsom AR; Chambless LE; Ballantyne CM; Coresh J; Heiss G; Wu KK; Boerwinkle E; Mosley TH; Sorlie P; Diao G; Sharrett AR
    Arch Intern Med; 2006 Jul; 166(13):1368-73. PubMed ID: 16832001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory markers of coronary risk.
    Rader DJ
    N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
    [No Abstract]   [Full Text] [Related]  

  • 8. [Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?].
    Piñón P; Kaski JC
    Rev Esp Cardiol; 2006 Mar; 59(3):247-58. PubMed ID: 16712749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
    Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
    N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
    Shane E; Addesso V; Namerow PB; McMahon DJ; Lo SH; Staron RB; Zucker M; Pardi S; Maybaum S; Mancini D
    N Engl J Med; 2004 Feb; 350(8):767-76. PubMed ID: 14973216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New tests for heart disease: promise but no payoff. Three new blood tests designed to detect early heart disease aren't quite ready for prime time.
    Harv Heart Lett; 2005 Jul; 15(11):6--7. PubMed ID: 16149177
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone loss after cardiac transplantation.
    Lindsay R
    N Engl J Med; 2004 Feb; 350(8):751-4. PubMed ID: 14973219
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.
    Moriarty PM; Gibson CA
    Am J Cardiol; 2005 May; 95(10):1246-7. PubMed ID: 15878003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
    Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.
    Kuvin JT; Dave DM; Sliney KA; Mooney P; Patel AR; Kimmelstiel CD; Karas RH
    Am J Cardiol; 2006 Sep; 98(6):743-5. PubMed ID: 16950175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
    Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
    Am J Cardiol; 2006 Mar; 97(5):640-5. PubMed ID: 16490429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
    Hoefle G; Holzmueller H; Drexel H
    N Engl J Med; 2004 May; 350(22):2306-8; author reply 2306-8. PubMed ID: 15168422
    [No Abstract]   [Full Text] [Related]  

  • 19. CRP: star trekking the galaxy of risk markers.
    Després JP
    Lancet; 2011 Feb; 377(9764):441-2. PubMed ID: 21277015
    [No Abstract]   [Full Text] [Related]  

  • 20. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
    Wootton PT; Stephens JW; Hurel SJ; Durand H; Cooper J; Ninio E; Humphries SE; Talmud PJ
    Atherosclerosis; 2006 Nov; 189(1):149-56. PubMed ID: 16438975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.